| Non-Hodgkin Lymphoma (NHL) |
1 |
1 |
| Food and Drug Administration (FDA) |
0 |
0.99 |
| Biologic Therapy |
0 |
0.58 |
| HIV Infection |
0 |
0.53 |
| Otolaryngology |
0 |
0.49 |
| Toxicology |
0 |
0.49 |
| Pain Management |
0 |
0.4 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.38 |
| Clinical Research |
0 |
0.37 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.37 |
| Small Molecule Inhibitor |
0 |
0.35 |
| Hodgkin Lymphoma |
0 |
0.27 |
| Mantle Cell Lymphoma |
0 |
0.27 |
| Hemorrhage |
0 |
0.25 |
| Lymphoma |
0 |
0.25 |
| Neutropenia |
0 |
0.25 |
| Pneumonia |
0 |
0.25 |
| Platelet Count |
0 |
0.21 |
| Targeted Cancer Therapy |
0 |
0.21 |
| Chronic Lymphocytic Leukemia |
0 |
0.18 |
| Upper Respiratory Tract Infection |
0 |
0.17 |
| Diarrhea |
0 |
0.13 |
| Influenza |
0 |
0.13 |
| Patient Safety |
0 |
0.13 |
| Adverse Effects |
0 |
0.12 |
| Cancer |
0 |
0.12 |
| Cough |
0 |
0.12 |
| Fever |
0 |
0.12 |
| Hemoglobin |
0 |
0.12 |
| Leukemia |
0 |
0.12 |
| Pain |
0 |
0.12 |
| Refractory |
0 |
0.12 |
| Respiratory Tract |
0 |
0.12 |
| Tyrosine Kinase |
0 |
0.12 |